Apricus Biosciences Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Apricus Biosciences

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: OldBoar who wrote (1812)	4/2/2016 1:38:13 AM
From: Mirror Image	of 2026

As far as I know - Sarissa - is allowed to appoint one person to the Board of Directors. That announcement alone would - in my opinion - have a positive effect on the Share price. What would be the reason for them not to do that - at this point? Do they benefit from the share price being walked down? Only if they are buying - or will be buying. A hard lesson for us long term holders is the fact that the market doesn't think much of Vitaros. But at which point is the company too cheap? As of today's close - Our Market Cap is 33 Million! Just the opt-in for Vitaros USA rights is 25 Million. Granted - we don't know with 100% certainty that we can clear that hurdle. And since I am on that subject. I read on earlier posts about concerns regarding the batch issues and it having an effect of having the FDA ask Apricus for further clinical trials. Wouldn't that be a Manufacturing Issue? In other words, a CMC Issue? Clinical Trials would be required if the FDA cites clinical or preclinical deficiencies. I do not believe that the European batch issue - in itself - would be the reason for further Clinical Trials for U.S. approval.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next